FEASIBILITY, TOLERANCE AND EFFICACY OF INTERFERON-FREE, ANTIVIRAL TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR THE TREATMENT OF GENOTYPE 2 AND SOFOSBUVIR/LEDIPASVIR FOR THE TREATMENT OF GENOTYPE 1 AND 4 HEPATITIS C VIRUS-INFECTED PATIENTS IN WEST AND CENTRAL AFRICA: